Risk adjusted net present value: What is the current valuation of Teva Pharmaceutical Industries’s Denosumab Biosimilar?

Denosumab Biosimilar is a monoclonal antibody commercialized by Teva Pharmaceutical Industries, with a leading Phase III program in Post Menopausal Osteoporosis.

Source link
#Risk #adjusted #net #present #current #valuation #Teva #Pharmaceutical #Industriess #Denosumab #Biosimilar